Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 12, December 2008 1957

Table. Knowledge of human risks associated with avian influenza, European region, 2006*

| Transmission risks                                                                 | Response, no. (%) |
|-----------------------------------------------------------------------------------|------------------|
| The avian influenza virus can be transmitted between humans                        | True  9,864 (33.8) | False 16,574 (56.8) | Don’t know 2,732 (9.4) |
| Humans can catch avian influenza by touching contaminated birds                    | True 22,722 (77.9) | False 4,473 (15.3)  | Don’t know 1,975 (6.8) |

| Food-related risks                                                               |                   |
|-----------------------------------------------------------------------------------|------------------|
| Even when it is contaminated, poultry is not a health risk if it is cooked         | True 17,906 (61.4) | False 8,536 (29.3)  | Don’t know 2,728 (9.4) |
| The avian influenza virus contained in an egg or present on its shell can be     | True 17,369 (59.5) | False 6,593 (22.6)  | Don’t know 5,208 (17.9) |
| eliminated by prolonged cooking                                                   |                   |
| It is not dangerous to eat the meat of a chicken vaccinated against avian         | True 12,833 (44.0) | False 9,272 (31.8)  | Don’t know 7,065 (24.2) |
| influenza                                                                         |                   |

| Other                                                                               |                   |
|-----------------------------------------------------------------------------------|------------------|
| The vaccination against seasonal influenza is also effective against avian         | True 4,265 (14.6)  | False 20,847 (71.5) | Don’t know 4,058 (13.9) |
| influenza                                                                          |                   |
| If a chicken is contaminated by avian influenza on a farm, all the poultry          | True 24,492 (84.0) | False 2,725 (9.3) | Don’t know 1,953 (6.7) |
| on that farm must be destroyed immediately                                         |                   |

*Source: Eurobarometer 65.2 (http://ec.europa.eu/public_opinion/archives/eb/eb65/eb65_eee_exec.pdf). Information in boldface refers to the correct answer.

and human-to-human virus transmission leaves areas for further work.

These results support previous findings that knowledge about avian influenza, especially about prevention and human-to-human transmission, has scope for improvement (4,5). Persons in Europe reported that they have little ability to prevent themselves from getting avian influenza (6). Previous research in the Lao People’s Democratic Republic examined how consumers’ knowledge of avian influenza risk reduced the likelihood that consumers will substitute poultry for other foods during an avian influenza crisis. This research indicates the importance of informing persons about consumption and transmission-related risks to reduce the likelihood of unnecessary behavioral changes that can cause larger macrolevel market effects (7).

The state of knowledge about avian influenza in Europe during the outbreak in the spring of 2006 leaves room for further public health information campaign efforts, especially those that increase consumers’ understanding of consumption-related avian influenza risks. Persons in Europe appear to be aware of culling procedures and the risks of touching infected birds but have a more limited understanding of how avian influenza in their region should influence their consumption patterns.

Elias Mossialos and Caroline Rudisill
Author affiliation: London School of Economics, London, UK

Address for correspondence: Caroline Rudisill, London School of Economics, LSE Health, Cowdray House, Houghton St, London WC2 2AE, UK; email: a.c.rudisill@lse.ac.uk

DOI: 10.3201/eid1412.080858

References

1. Sanco DG. Confirmed human cases of avian influenza since 1997 sorted by subtypes [cited 2008 May 27]. Available from http://ec.europa.eu/health/ph_threats/com/influenza/avian_influenza_human_en.htm
2. Eurobarometer. Avian influenza June 2006 [cited 2008 Mar 15]. Available from http://ec.europa.eu/public_opinion/archives/eb/esb/esb_257_en.pdf
3. World Health Organization. H5N1 avian influenza: timeline of major events [cited 2008 May 22]. Available from http://www.who.int/csr/disease/avian_influenza/ai_timeline/en/index.html
4. Abbate R, Di Giuseppe G, Marinelli P, Angelillo IF. Knowledge, attitudes, and practices of avian influenza, poultry workers, Italy. Emerg Infect Dis. 2006;12:1762–5.
5. Di Giuseppe G, Abbate R, Albano L, Marinelli P, Angelillo IF. A survey of knowledge, attitudes and practices towards avian influenza in an adult population of Italy. BMC Infect Dis. 2008;8:36.
6. De Zwart O, Veldhuijzen IK, Elam G, Aro AR, Abraham T, Bishop GD, et al. Avian influenza risk perception, Europe and Asia. Emerg Infect Dis. 2007;13:290–3.
7. Suder G, Intahavong S. New health risks and sociocultural contexts: bird flu impacts on consumers and poultry business in Lao PDR. Risk Anal. 2008;28:1–12. DOI: 10.1111/j.1539-6924.2008.00997.x

Human Salmonella Infection Yielding CTX-M β-Lactamase, United States

To the Editor: In the United States most third-generation cephalosporin resistance among salmonellae is due to AmpC plasmid-mediated β-lactamases. Extended-spectrum β-lactamases (ESBLs) have rarely been reported (1). The CTX-M β-lactamases constitute a group of ESBL enzymes that are increasing in prevalence worldwide. Currently, the CTX-M enzymes are classified into 5 different subgroups on the basis of DNA sequence similarities (2). We report on a domestically acquired CTX-M–producing Salmonella isolate in the United States.

In 2003, public health laboratories in all US state health departments submitted every 20th non-Typhi Salmonella (NTS) isolate from humans...
to the Centers for Disease Control and Prevention (CDC) for susceptibility testing by the National Antimicrobial Resistance Monitoring System (NARMS). MICs were determined by broth microdilution and interpreted according to Clinical and Laboratory Standards Institute standards (www.clsi.org), when available. Resistance to cefquinome was defined as ≥32 mg/L.

Among the 1,864 human NTS isolates submitted to NARMS in 2003, 105 (5.6%) displayed elevated MICs (≥2 mg/L) to ceftriaxone or cefotaxime, third-generation cephalosporins used in human and veterinary medicine, respectively. Genomic DNA was prepared from the 105 isolates, and a PCR with degenerate primers capable of detecting all CTX-M enzymes identified a single positive S. enterica ser. Typhimurium (3). The isolate came from a stool sample collected in September 2003 from a white, non-Hispanic, US-born, 3-month-old boy who lived in the state of Georgia. The patient had diarrhea and fever for ≈1 week. Because neither the patient nor his family had traveled internationally in the 3 months before specimen collection, the infection appears to have been domestically acquired. The patient did not receive any antimicrobial agents before illness but was treated for 14 days with cefpodoxime. The infant recovered from the illness without complications.

The isolate displayed resistance to β-lactams, aminoglycosides, phenicols, tetracyclines, and folate pathway inhibitors (Table). Two β-lactamases (isoelectric pH [pI] 7.5 and 8.8) were resolved by isoelectric focusing. The genetic environment of the β-lactamase gene was investigated by PCR specific for upstream insertion elements (ISecep1, IS26, and ORF513) and the downstream sequence sul1 (5). Amplification with primer ISecep1 and an internal blaCTX-M5 primer yielded a PCR product of ≈350 bp. Sequencing confirmed presence of the 3′ end inverted repeat region of the ISecep1.

To determine whether the CTX-M enzyme was plasmid-borne, plasmids were extracted and transformed into electrocompetent Escherichia coli DH10B. The transformant exhibited resistance to cefotaxime but not to cefazidime (Table). In addition, the transformant exhibited resistance to cefquinome and cefepime. The presence of a blaCTX-M5 gene was confirmed by PCR (3,4). The blaOXA gene could not be amplified from the E. coli transformant (8).

A CTX-M–producing Salmonella isolate has been reported only once previously in the United States (9). This was in 1994, when an isolate of Salmonella ser. Typhimurium var. Copenhagen with a CTX-M-5 was recovered from a 4-month-old girl adopted from Russia; that infection was not domestically acquired (9). We compared the 1994 isolate and the isolate in this study by pulsed-field gel electrophoresis; the isolates showed distinct patterns.

### Table. MIC values of antimicrobial drugs for the Salmonella ser. Typhimurium isolate and its Escherichia coli DH10B transformant

| Antimicrobial agent | S. ser. Typhimurium | E. coli DH10B transformant | E. coli DH10B |
|---------------------|----------------------|---------------------------|--------------|
| Amikacin            | 1                    | 1                         | 1            |
| Amoxicillin–clavulanic acid | 32               | 16                       | 4            |
| Ampicillin          | >32                  | >32                       | 4            |
| Aztreonam           | 32                   | 32                        | 0.12         |
| Cefepine            | 32                   | 32                        | ≤0.06        |
| Cefotaxime          | >64                  | >64                       | ≤0.06        |
| Cefotaxime–clavulanic acid | 0.25             | 0.12                      | ≤0.06        |
| Cefoxitin           | 2                    | 8                         | 8            |
| Cefquinome          | >32                  | >32                       | ≤0.06        |
| Ceftazidime         | 8                    | 8                         | 0.5          |
| Ceftazidime–clavulanic acid | 0.5               | 0.25                      | 0.12         |
| Ceftiofur           | >8                   | >8                        | 0.5          |
| Ceftriaxone         | >64                  | >64                       | ≤0.25        |
| Chloramphenicol     | >32                  | ≤2                        | ≤2           |
| Ciprofloxacin       | ≤0.016               | ≤0.016                    | ≤0.016       |
| Gentamicin          | 4                    | ≤0.25                     | ≤0.25        |
| Imipenem            | 0.5                  | 0.25                      | 0.25         |
| Kanamycin           | >64                  | ≤8                        | <8           |
| Nalidixic acid      | 4                    | 1                         | 1            |
| Piperacillin-tazobactam | >64             | 2                         | 2            |
| Streptomycin        | ≤32                  | >64                       | >64          |
| Sulfoxazole         | >256                 | ≤16                       | ≤16          |
| Tetracycline        | >32                  | ≤4                        | ≤4           |
| Trimethoprim-sulfamethoxazole | >4              | ≤0.12                     | ≤0.12        |
The ISEcpl insertion sequence has been described as a flanking region of several blaCTX-M genes and has been implicated in the expression and mobilization of the genes (5). A recent study by Lartigue et al. showed that a CTX-M-2 progenitor in K. ascorbata could be mobilized and transferred to a conjugative E. coli plasmid by the ISEcplB element; enhanced mobilization was observed in the presence of cefazidime, cefotaxime, and piperacillin (10).

This Salmonella isolate’s resistance to cefepime and ceftazidime, fourth-generation cephalosporins, is troubling. Ceftazidime is not approved for use in the United States but has been used in Europe for treating food animals since 1994. ESBLs, including CTX-M enzymes, are more common in Europe than in the United States (1). Further studies are warranted to clarify the extent to which the use of ceftazidime has contributed to high CTX-M prevalence in Europe.

In conclusion, we report a domestically acquired CTX-M-producing Salmonella isolate in the United States. Because third-generation cephalosporins are important for treating invasive Salmonella infections, continued monitoring of ESBL-producing bacteria is important.

Acknowledgments

We thank the NARMS-participating public health laboratories for submitting isolates, Matt Mikelit for confirming the Salmonella serotype, Anne Whitney for DNA sequencing, and the Georgia Division of Public Health for providing patient interview information.

This work was supported by an inter-agency agreement between CDC and the Food and Drug Administration Center for Veterinary Medicine.

Maria Sjölund, Jennifer Yam, Jillian Schwenk, Kevin Joyce, Felicita Medalla, Ezra Barzilay, and Jean M. Whichard

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Sjölund, J. Yam, J. Schwenk, K. Joyce, F. Medalla, E. Barzilay, J.M. Whichard); and Atlanta Research and Education Foundation, Atlanta (M. Sjölund, J. Yam, K. Joyce).

DOI: 10.3201/eid1412.080494

References

1. Bush K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infect. 2008;14(Suppl 1):134–43. DOI: 10.1111/j.1469-0691.2007.01848.x
2. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14. DOI: 10.1128/AAC.48.1.1-14.2004
3. Bonnet R, Reculet C, Baraduc R, Chantal C, Sirot D, De Champs C, et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother. 2003;52:29–35. DOI: 10.1093/jac/dkg256
4. Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol. 2004;42:5715–21. DOI: 10.1128/JCM.42.12.5715-5721.2004
5. Eckert C, Gauthier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249–55. DOI: 10.1128/AAC.48.4.1249-1255.2004
6. Brinas L, Zarazaga M, Saenz Y, Ruiz-Larrea F, Torres C. Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother. 2002;46:3156–63. DOI: 10.1128/AAC.46.10.3156-3163.2002
7. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother. 1997;41:647–53.
8. Chen S, Zhao S, White DG, Schroeder CM, Lu R, Yang H, et al. Characterization of multiple-antimicrobial-resistant salmonella serovars isolated from retail meats. Appl Environ Microbiol. 2004;70:1–7. DOI: 10.1128/AEM.70.1.1-7.2004
9. Zirnstein G, Swaminathan B, Angulo F, Tenover F, Rasheed JK. Plasmid-mediated CTX-M-5 beta-lactamase conferring resistance to ceftriaxone and cefotaxime in a Salmonella serotype Typhimurium var. Copenhagen isolate from an infant adopted from Russia. In: Proceedings of the 2nd International Conference on Emerging Infectious Diseases, Atlanta, Georgia, USA. July 16–19, 2000. Washington: American Society for Microbiology; 2000.
10. Lartigue MF, Poiré L, Aubert D, Nordmann P. In vitro analysis of ISEcplB-mediated mobilization of naturally occurring beta-lactamase gene blaCTX-M of Kluyvera ascorbata. Antimicrob Agents Chemother. 2006;50:1282–6. DOI: 10.1128/AAC.50.4.1282-1286.2006

Address for correspondence: Maria Sjölund, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G29, Atlanta GA 30333, USA; email: fwt4@cdc.gov

Yersinia pseudotuberculosis

0:1 Traced to Raw Carrots, Finland

To the Editor: Illness caused by Yersinia pseudotuberculosis is mainly characterized by fever and acute abdominal pain due to mesenteric lymphadenitis that mimics appendicitis. Secondary manifestations include erythema nodosum and reactive arthritis (1). Outbreaks have been reported in the Northern Hemisphere, including Canada (2,3), Japan (4), and Russia (5). Several community outbreaks have also been reported in Finland since 1982 (1,6–9). Only in a few of the outbreaks has the vector or source of the infection been identified. Recently, fresh produce, such as iceberg lettuce (7) and carrots (9), has been implicated by epidemiologic investigations as a source of infection, but mechanisms of contamination of fresh produce have remained unknown.

On April 8, 2004, the National Public Health Institute of Finland was informed of several cases of gastroin